Ipamorelin Accelerates Bowel Recovery After Surgery, Reducing Postoperative Ileus

Postoperative ileus (POI), a temporary paralysis of the bowel, is a frequent and debilitating complication following abdominal surgery, particularly bowel resection. It significantly delays patient recovery, prolongs hospital stays, and increases healthcare costs. Current management strategies are largely supportive and lack specific pharmacological interventions to accelerate gastrointestinal (GI) motility. This prospective, randomized, controlled, proof-of-concept study aimed to evaluate the efficacy of ipamorelin, a ghrelin mimetic, in reducing the duration of POI and accelerating GI recovery in patients undergoing bowel resection.

The study's primary endpoint, time to first bowel movement (BM), was significantly reduced in the ipamorelin group. Patients receiving ipamorelin achieved their first BM in a median of 3.8 days, compared to 4.6 days in the placebo group, representing a statistically significant reduction of 0.8 days (p=0.04). This indicates that ipamorelin treatment led to a 20% faster return of normal bowel function compared to the placebo, accelerating recovery from postoperative ileus. Secondary endpoints, such as time to tolerating solid food and hospital discharge, also showed trends towards improvement, though not all reached statistical significance in this proof-of-concept study. The safety profile was comparable between both groups, with no significant increase in adverse events attributed to the ghrelin mimetic.